Zika vaccine could be delayed, unaffordable after US Army grants exclusive rights to pharma company

The U.S. government wants to sign an exclusive deal with French pharma giant Sanofi to further develop and roll out a new vaccine that could help halt the spread of Zika. NGOs, including MSF, think the vaccine technology, which was developed using tax payers' money, should be shared with other companies too and argue this will ensure the vaccine gets developed faster and is made affordable to people in middle-income and developing countries.

About the author

  • Sophie Edwards

    Sophie Edwards is a Reporter for Devex based in London covering global development news including global education, water and sanitation, innovative financing, the environment along with other topics. She has previously worked for NGOs, the World Bank and spent a number of years as a journalist for a regional newspaper in the U.K. She has an MA from the Institute of Development Studies and a BA from Cambridge University.